Rise and shine, everyone, another busy week is on the way. We hope the weekend was refreshing, but now the time has come to gear up once again for all those meetings and deadlines and whatever else occupies your day. In fact, we are prepping for some important sessions ourselves later this week. As always, this calls for a cup or three of delicious stimulation. Our flavor today is Southern Pecan. Please feel free to join us, of course. Meanwhile, here is your usual menu of interesting tidbits to get you started. Hope your day goes well and do drop us a line if you hear of something interesting. Cheers...
Affymax Anemia Side Effects Showed Up Early (Wall Street Journal)
FDA Approves J&J Diabetes Drug (Associated Press)
Biogen Prices New MS Pill Below Rival Meds (Reuters)
Australia Could Save $1.3B By Negotiaing Rx Prices (News.AU)
GERD Label Makes Parents More Likely To Want Med (Reuters)
Vitamin D May Lower High Blood Pressure: Study (NPR)
Alzheimer's Death Rate Outpaces Other Illnesses (MedCity News)
EDITOR'S NOTE: Please check this post for additional stories during the day
steaming coffee pic thx to dleggett on flickr
1 Comment
If there was no such thing as neonatal and pediatric GERD the FDA would not have issued a Written Request and we would not have spent $20 million to get the pediatric exclusivity and indication on Axid OS back in 2002. Granted the disease is rare and we had to go global to get enough patients but the stuff has a nice bubble gum flavor and the kids love it so much they stop crying right after the first chug, which is worth the approval to the moms, I garontee. I also agree that having to to an intraesophageal pH measurement on a neonate is challenging, but this is what FDA made us do to verify the dx.
In real practice 99% of these babies have non pathological NERD (nonerosive reflux disease). But if you were a pediatrician what would compel you to dose the kid more, a dx of GERD or NERD?
http://www.fda.gov/ohrms/dockets/ac/02/briefing/3870B1_03_Sample%20Request%20.htm